Adenosine A1 receptor activator T62结构式
|
常用名 | Adenosine A1 receptor activator T62 | 英文名 | T62 |
|---|---|---|---|---|
| CAS号 | 40312-34-3 | 分子量 | 291.79600 | |
| 密度 | 1.337g/cm3 | 沸点 | 527ºC at 760 mmHg | |
| 分子式 | C15H14ClNOS | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | 272.5ºC |
|
Allosteric adenosine receptor modulation reduces hypersensitivity following peripheral inflammation by a central mechanism.
J. Pharmacol. Exp. Ther. 305 , 950-955, (2003) Activation of adenosine A1 receptors by endogenous adenosine or synthetic agonists produces antinociception in animal models of acute pain and also reduces hypersensitivity in models of inflammatory and nerve-injury pain. Allosteric adenosine modulators facil... |
|
|
Repeated dosing with oral allosteric modulator of adenosine A1 receptor produces tolerance in rats with neuropathic pain.
Anesthesiology 100(4) , 956-61, (2004) The positive allosteric adenosine receptor modulator, T62 (2-amino-3-(4-chlorobenzoyl)-5,6,7,8-tetrahydrobenzothiophene), has been shown to reduce mechanical allodynia in a rat model of neuropathic pain. However, whether chronic oral T62 retains efficacy in t... |
|
|
Allosteric modulation of G protein-coupled receptors: perspectives and recent developments.
Drug Discov. Today 9 , 752-758, (2004) Allosteric modulation of G protein-coupled receptors has recently been recognized as an alternative approach to gain selectivity in drug action. In this overview, allosteric modulators that enhance or diminish the effects of (endogenous) agonists or antagonis... |
|
|
Spinal adenosine receptor activation reduces hypersensitivity after surgery by a different mechanism than after nerve injury.
Anesthesiology 100 , 1258-1262, (2004) Intrathecal adenosine has antinociceptive effects under conditions of hypersensitivity. T62 (2-amino-3-(4-chlorobenzoyl)-5,6,7,8-tetrahydrobenzothiophen) is an allosteric adenosine receptor modulator that enhances adenosine binding to the A1 receptor. Intrath... |
首页 |
期刊大全 |
MSDS查询 |
化工产品分类 |
生物活性化合物 |
关于我们 |
免责声明:知识产权问题请联系 service1@chemsrc.com
Copyright © 2024 ChemSrc All Rights Reserved
